SRRK - スカラ―・ロック・ホ―ルディング （Scholar Rock Holding Corporation） スカラ―・ロック・ホ―ルディングSRRKのチャート
SRRKの企業情報
| symbol | SRRK |
|---|---|
| 会社名 | Scholar Rock Holding Corp （スカラ―・ロック・ホ―ルディング） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 スカラー・ロック・ホールディング(Scholar Rock Holding Corporation)は生物医薬品企業である。同社は、神経筋障害、癌、線維症および貧血などの疾患の治療用モノクローナル抗体の開発に従事する。同社のリード製品候補は、開発の前臨床段階にあるSRK-015である。SRK-015は骨格筋における成長因子ミオスタチンの活性化の選択的阻害剤であり、脊髄性筋萎縮症（SMA）の治療に使用される。同社はまた、TGFβ1およびBMP6を含む他の抗体プログラムを開発する。TGFβ1抗体プログラムはTGFβ1メンバーの特異的阻害剤である抗体の開発を中心とする。 スカラ―・ロック・ホ―ルディングは米国のバイオ医薬品系持株会社。子会社を通じ、神経筋疾患、がん、線維症、貧血などを含む重篤疾患を治療するための新薬の発見、開発に従事する。同社の主力製品は脊髄性筋萎縮症患者の治療用に開発されたSRK-015。本社所在地はマサチュ―セッツ州ケンブリッジ。 Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. Scholar Rock's approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path. |
| 本社所在地 | 620 Memorial Drive 2nd Floor Cambridge MA 02139 USA |
| 代表者氏名 | David L. Hallal デイビッド・L・ハラル |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 857-259-3860 |
| 設立年月日 | 2017年 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | 50人 |
| url | www.scholarrock.com |
| nasdaq_url | https://www.nasdaq.com/symbol/srrk |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -37.60200 |
| 終値（lastsale） | 22.01 |
| 時価総額（marketcap） | 555613484.84 |
| 時価総額 | 時価総額（百万ドル） 526.58330 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 412.25330 |
| 当期純利益 | 当期純利益（百万ドル） -37.98500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Scholar Rock Holding Corp revenues was not reported. Net loss increased from $10.6M to $23.6M. Higher net loss reflects Research and development - Balancing val increase from $5.7M to $13M (expense) General and administrative - Balancing v increase from $4.5M to $9.4M (expense) Stock-based Compensation in R&D increase from $226K to $787K (expense). |
SRRKのテクニカル分析
SRRKのニュース
Piper Sandler Assumes Scholar Rock at Overweight 2023/04/03 09:01:04 Investing.com
https://www.investing.com/news/pro/piper-sandler-assumes-scholar-rock-at-overweight-432SI-3047368
Scholar Rock GAAP EPS of -$2.26 beats by $0.02, revenue of $33.19M in-line 2023/03/07 12:50:29 Seeking Alpha
Scholar Rock press release (NASDAQ:SRRK): FY GAAP EPS of -$2.26 beats by $0.02.Revenue of $33.19M (+76.4% Y/Y) in-line.
Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress 2023/03/07 12:00:00 Business Wire
Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth f
Scholar Rock to Present at the Cowen 43rd Annual Health Care Conference 2023/02/27 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023, at 12:50 p.m. ET. A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2023/02/17 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the Company granted inducement equity awards covering an aggregate of 285,000 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 255,000 shares of common stock and induceme
Scholar Rock GAAP EPS of -$1.06 misses by $0.02 2022/08/08 21:47:57 Seeking Alpha
Scholar Rock press release (SRRK): Q2 GAAP EPS of -$1.06 misses by $0.02.As of June 30, 2022, Scholar Rock had cash, cash equivalents, and marketable securities of approximately…
Scholar Rock Reports Second Quarter 2022 Financial Results and Highlights Business Progress 2022/08/08 20:15:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the second quarter ended June 30, 2022. “We are pleased to have reported important progress with our two clinical programs during the second quarter. Enrollment continues to advance in our pivotal Phase 3 SAPPHIRE trial for
Scholar Rock Holding Corporation (NASDAQ: SRRK) Is An Exciting Stock To Watch. 2022/08/06 16:00:00 Stocks Register
Scholar Rock Holding Corporation (NASDAQ:SRRK) shares, rose in value on Friday, 08/05/22, with the stock price up by 21.26% to the previous day’s close as strong demand from buyers drove the stock to $8.50. Actively observing the price movement in the last trading, the stock closed the session at $7.01, falling within a range of … Scholar Rock Holding Corporation (NASDAQ: SRRK) Is An Exciting Stock To Watch. Read More »
We Just Learned Something New About Scholar Rock Holding Corporation (NASDAQ: SRRK) This Week With Its -4.77% Loss 2022/07/16 13:00:00 Marketing Sentinel
During the last session, Scholar Rock Holding Corporation (NASDAQ:SRRK)’s traded shares were 0.45 million, with the beta value of the company hitting 0.56. At the end of the trading day, the stock’s price was $7.98, reflecting an intraday loss of -0.62% or -$0.05. The 52-week high for the SRRK share is $44.95, that puts it … We Just Learned Something New About Scholar Rock Holding Corporation (NASDAQ: SRRK) This Week With Its -4.77% Loss Read More »
Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology 2022/07/12 16:14:19 Seeking Alpha
Truist has initiated Scholar Rock Holding Corp (SRRK) with a buy citing the company''s validated platform that targeting growth factors for rare disease and oncology indications.
We Just Learned Something New About Scholar Rock Holding Corporation (NASDAQ: SRRK) This Week With Its -4.77% Loss 2022/07/16 13:00:00 Marketing Sentinel
During the last session, Scholar Rock Holding Corporation (NASDAQ:SRRK)’s traded shares were 0.45 million, with the beta value of the company hitting 0.56. At the end of the trading day, the stock’s price was $7.98, reflecting an intraday loss of -0.62% or -$0.05. The 52-week high for the SRRK share is $44.95, that puts it … We Just Learned Something New About Scholar Rock Holding Corporation (NASDAQ: SRRK) This Week With Its -4.77% Loss Read More »
Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology 2022/07/12 16:14:19 Seeking Alpha
Truist has initiated Scholar Rock Holding Corp (SRRK) with a buy citing the company''s validated platform that targeting growth factors for rare disease and oncology indications.
Thinking about buying stock in Inmode, Evofem Biosciences, Scholar Rock, Verrica Pharmaceuticals, or Indonesia Energy? 2022/07/12 13:35:00 Kwhen Finance
Thinking about buying stock in Inmode, Evofem Biosciences, Scholar Rock, Verrica Pharmaceuticals, or Indonesia Energy? 2022/07/12 13:35:00 Benzinga
NEW YORK , July 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INMD, EVFM, SRRK, VRCA, and INDO. … Full story available on Benzinga.com
Why Is DoorDash Down By 8%? 38 Stocks Moving In Wednesday''s Mid-Day Session 2022/07/06 16:08:47 Benzinga
Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN ) shares surged 69.5% to $2.1199 after the company announced it has developed a non-invasive blood sensor designated to alert real-time change in patients'' clinical condition. Resolute Forest Products Inc. (NYSE: RFP ) shares jumped 63.9% to $20.47 after The Paper Excellence Group announced an agreement to acquire the company. SCWorx Corp. (NASDAQ: WORX ) jumped 52% to $0.9425 after the company reported a common stock purchase agreement with institutional investor on Tuesday. Enjoy Technology, Inc. (NASDAQ: ENJY ) jumped 50% to $0.4651 after jumping more than 80% on Tuesday. Kalera Public Limited Company (NASDAQ: KAL ) shares climbed 28.6% to $3.6001 after dipping 22% on Tuesday. Engine Gaming and Media, Inc. (NASDAQ: GAME ) gained 27.2% to $1.17. Engine Gaming and Media is expected to release fiscal third quarter results on Thursday, July 14, 2022. Sintx Technologies, Inc. (NASDAQ: SINT ) jumped 27% to $0.5210. SINTX Technologies earlier announced acquisition of Technology Assessment and Transfer, Inc.